SPY414.92-5.67 -1.35%
DIA332.96-5.20 -1.54%
IXIC14,030.38-130.97 -0.92%

BRIEF-Diffusion Pharmaceuticals Reports Final Results From Its Phase 1B Study Of Trans Sodium Crocetinate In Hospitalized Covid-19 Patients

05/10/2021 07:56
BRIEF-Diffusion Pharmaceuticals Reports Final Results From Its Phase 1B Study Of Trans Sodium Crocetinate In Hospitalized Covid-19 Patients

- Diffusion Pharmaceuticals Inc DFFN.O:

  • DIFFUSION PHARMACEUTICALS REPORTS FINAL RESULTS FROM ITS PHASE 1B STUDY OF TRANS SODIUM CROCETINATE IN HOSPITALIZED COVID-19 PATIENTS

  • DIFFUSION PHARMACEUTICALS - 1 DEATH WAS REPORTED DURING STUDY, A PATIENT WHO RECEIVED LOWEST DOSE & WHICH WAS DETERMINED BY SMC TO BE NOT DRUG RELATED

  • DIFFUSION PHARMACEUTICALS INC - ANTICIPATES INITIATING AND COMPLETING DLCO TRIAL AND INDUCED HYPOXIA TRIAL IN SECOND HALF OF 2021

  • DIFFUSION PHARMA - OBSERVED THAT PATIENTS RECEIVING 1.5 MG/KG DOSE HAD IMPROVED OUTCOMES IN SECONDARY AND EXPLORATORY ENDPOINTS VERSUS LOWER DOSES

  • DIFFUSION PHARMACEUTICALS INC - NO PATIENTS REQUIRED DIALYSIS OR DEVELOPED ACUTE KIDNEY INJURY

  • DIFFUSION PHARMACEUTICALS INC - THERE WERE NO REPORTS OF PULMONARY EMBOLISM OR DEEP VEIN THROMBOSIS

Source text for Eikon: ID:nGNX5mftzQ

Further company coverage: DFFN.O


(([email protected];))